The Verhaak Lab
Brain tumors, sequencing, computational biology.
Brain tumors, sequencing, computational biology.
We are a computational cancer biology lab with a research focus on the analysis of cancer genomics data to improve our understanding of cancer biology. We have a specialized research interest in understanding disease progression of brain tumors, particularly glioblastoma and glioma. We mostly use high throughput sequencing and computational analysis in our research.
Dr. Roel Verhaak’s lab at The Jackson Laboratory for Genomic Medicine is currently seeking two recent graduates interested in investigating cancer and therapy resistance.
We are looking for a molecular biologist experienced in cell culture and lentiviral transfection who will be investigating the evolution of individual glioblastoma (GBM) cells using single cell barcoding technology and comprehensively characterized GBM model systems. The goal of this study is to trace clonal evolution in GBM, to evaluate the genomic properties of dominant, therapy resistant clones relative to therapy sensitive cells and to compare findings in model systems with observations from clinical tumors. The ideal candidate has affinity for data analysis but experience with sequencing data (-analysis) is not a requirement.
We are also looking for computational biologists or researchers from associated disciplines to strengthen our computational analysis group. We offer a wide range of projects, including studies of extrachromosomal DNA in the context of cancer evolution which involves long read sequencing analysis; DNA methylation and transcriptome single cells studies; nucleosome analysis; and longitudinal analysis of glioma patient samples.
Barthel, F.P., Wei, W., Tang, M., Martinez-Ledesma, E., Hu, X, ... Verhaak, R.G. Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet. 2017.
Ceccarelli, M., Barthel, F. P., Malta, T. M., Sabedot, T. S., Salama, S. R., Murray, B. A., . . . Verhaak, R. G. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 164(3), 550-563. 2016.
Zheng, S., Cherniack, A. D., Dewal, N., Moffitt, R. A., Danilova, L., Murray, B. A., . . . Verhaak, R. G. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell, 29(5), 723-736. 2016.
Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, . . . . Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med, 372(26), 2481-2498. 2015.
Kim, H., Zheng, S., Amini, S. S., Virk, S. M., Mikkelsen, T., Brat, D. J., . . . Verhaak, R. G. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res, 25(3), 316-327. 2015.
Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L; TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell. 155(2):462-77. 2013.
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17(1):98-110. 2010.
Press release with comments from Francis Collins, John Niederhuber and Eric Gree
The mammalian immune system has developed surveillance mechanisms that can detect cancerous cells. However, successful tumor cells have...
Non-invasive evaluation of molecular markers has shifted from the realm of prenatal diagnosis to tracking the effect of cancer treatment...
Advance your research in genetics by harnessing the power of the mouse! This new graduate-level advanced genetics course will provide a...
Advance your research in genetics by harnessing the power of the mouse! This new graduate-level advanced genetics course will provide a...
Mouse models for acute myeloid leukemia are available with a wide range of genetic mutations and growth profiles more...
Professor Roel Verhaak, Ph.D., is focused on the analysis of cancer genomics data to improve our understanding of cancer...
We are committed to providing academic PIs the most innovative pre-clinical models and services to delineate the mechanisms underlying...
We provide access to many bladder cancer PDX models, including muscle-invasive options. Models are currently available for efficacy testing...
Over 20 unique breast cancer PDX models are currently available within our PDX model cancer collection, including the most common and...
Our PDX collection has over 50 unique lung cancer PDX models representing a diverse set of clinically relevant mutations currently observed...
We provide access to a large collection of ovarian PDX models currently available for efficacy testing at our facility or for distribution...
We provide access to a large collection of pancreatic cancer PDX models currently available for efficacy testing at our facility or for...
JAX In Vivo Pharmacology Services has experience with a range of common tumor cell lines and the capability to use customer provided cancer...
Humanized NSG™ (hu-NSG™) mice represent an innovative and cost-effective immuno-oncology platform to simulate trials, evaluate multiple...
Establishing PDX cohorts from frozen samples can extend drug efficacy studies 6-12 weeks or more. The inventoried PDX Live tumor program at...
JAX offers ten AML patient-derived xenograft (PDX) models with varying mutational profiles and treatment histories. These models are...
We use cookies to give you the best online experience.
By using our website you agree to our use of cookies in accordance with our cookie policy.